AbbVie Inc. (4AB.F)
| Previous close | 152.06 |
| Open | 152.02 |
| Bid | 153.36 x 60000 |
| Ask | 153.84 x 60000 |
| Day's range | 150.82 - 152.44 |
| 52-week range | 119.00 - 168.80 |
| Volume | |
| Avg. volume | 203 |
| Market cap | 269.189B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 48.86 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.77 (3.64%) |
| Ex-dividend date | 15 Jul 2024 |
| 1y target est | N/A |
- PR Newswire
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
- PR Newswire
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
AbbVie (NYSE: ABBV) today announced that Robert A. Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of Directors, effective today. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has served as CEO since the company's inception in 2013. Mr. Gonzalez has become executive chairman of the board of directors.
- PR Newswire
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional marketing authorization of epcoritamab (TEPKINLY®), the first and only T-cell engaging bispecific antibody administered subcutaneously (under the skin), as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more prior therapies. The Eur
